Eli Lilly (LLY) heads into 2026 with GLP-1 pricing and competition risks; oral GLP-1 race heats up and downside looms.

Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its ...

Nvidia and Eli Lilly are teaming up on a $1 billion AI-powered lab to accelerate drug discovery, combining robotics, molecular modeling and automated research workflows.

The Fischer Theatre will host a special film event uniting firefighters from across the nation, spotlighting a Wichita Fire ...

I agree to the Terms of Use , Privacy Notice and Cookie Notice.

Nvidia and U.S. pharma giant Eli Lilly will spend $1 billion building a new joint research lab in the San Francisco Bay area ...

France's Finance ​Ministry said on Monday it had received no formal request for investment approval ‌regarding French biotech ...

Indiana has a nearly $1 billion plan to ship water to the LEAP District. Utilities say they won't pass cost to consumers.

The market offers explosive potential as biology transitions to factory-scale production. Anchored by the USD 100 genome and ...

Indiana Attorney General Todd Rokita on Monday announced a new lawsuit against Indianapolis-based drug maker Eli Lilly and Co ...

Eli Lilly (LLY) achieved 54% year-over-year revenue growth to $17.6B in Q3. Tirzepatide is projected as the top-selling drug by 2030. Lilly raised its quarterly dividend 15% to $1.73 per share. The ...